{"id":11242,"date":"2020-11-24T11:15:08","date_gmt":"2020-11-24T05:45:08","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=11242"},"modified":"2023-02-10T11:42:02","modified_gmt":"2023-02-10T06:12:02","slug":"pharma-happenings-for-gilead-novartis-lilly-innovent","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-novartis-lilly-innovent","title":{"rendered":"Novartis&#8217; COVID-19 deal; Shattered hopes for Remdesivir; Lilly&#8217;s  R&#038;D pact with Precision; Innovent&#8217;s Humira Biosimilar"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69fb967fc0df9\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69fb967fc0df9\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-novartis-lilly-innovent\/#Novartis_bags_Mesoblasts_cell_therapy_Remestemcel-L_for_COVID-19_ARDS\" >Novartis bags Mesoblast&#8217;s cell therapy, Remestemcel-L for COVID-19 ARDS<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-novartis-lilly-innovent\/#WHO_recommends_against_the_use_of_remdesivir_to_treat_COVID-19_refutes_early_hopes\" >WHO recommends against the use of remdesivir to treat COVID-19, refutes early hopes<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-novartis-lilly-innovent\/#Lilly_forms_a_USD_555M_R_D_alliance_with_Precision_BioSciences_for_DMD_breakthrough_therapies\" >Lilly forms a USD 555M R&amp;D alliance with Precision BioSciences for DMD breakthrough therapies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-novartis-lilly-innovent\/#Innovent_receives_Chinas_NMPA_approval_for_its_Humira_Biosimilar_for_of_Polyarticular_Juvenile_Idiopathic_Arthritis\" >Innovent receives China\u2019s NMPA approval for its Humira Biosimilar for of Polyarticular Juvenile Idiopathic Arthritis<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Novartis_bags_Mesoblasts_cell_therapy_Remestemcel-L_for_COVID-19_ARDS\"><\/span><strong>Novartis bags Mesoblast&#8217;s cell therapy, Remestemcel-L for COVID-19 ARDS<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The COVID-19 pandemic has put tremendous pressure on scientists to develop a safe and effective vaccine as early as possible. According to the WHO, there are currently more than 100 <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-therapeutic-pipeline-vaccines\" target=\"_blank\" rel=\"noreferrer noopener\">COVID-19 vaccine candidates<\/a> under development, with several in the human trial phase. While earlier news came of the efficacy of the potential vaccines from Pfizer and Moderna, this time, it is about a new licensing deal between Novartis and Australia-based Mesoblast.&nbsp;<\/p>\n\n\n\n<p>Novartis has bagged an exclusive worldwide license to develop, commercialize, and manufacture <strong>remestemcel-L<\/strong>, Mesoblast\u2019s candidate for acute respiratory distress syndrome (ARDS). The company is paying Mesoblast USD 25 million upfront and USD 25 million investment in Mesoblast equity along with additional pre-commercialization milestone payments that could total USD 505 million and post-commercialization milestones up to USD 750 million.&nbsp;<\/p>\n\n\n\n<p>Remestemcel-L\u2019s immunomodulatory properties have the potential to counteract the overactive immune reaction known as a cytokine storm that is linked to COVID-19 and other inflammatory conditions. Thus, it is under the Phase III trial in COVID-19-related ARDS. The company plans to launch a Phase III trial in non-COVID-19-related <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-respiratory-distress-syndrome-ards-market\" target=\"_blank\" rel=\"noreferrer noopener\">ARDS<\/a> shortly after closing the deal.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"WHO_recommends_against_the_use_of_remdesivir_to_treat_COVID-19_refutes_early_hopes\"><\/span><strong>WHO recommends against the use of remdesivir to treat COVID-19, refutes early hopes<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>While therapeutic agents and vaccines are lining up in ques, the fate of therapies remains unpredictable. A once-promising treatment against COVID-19, <a href=\"https:\/\/www.delveinsight.com\/whitepaper-newsletter\/remdesivir-in-covid-19\" target=\"_blank\" rel=\"noreferrer noopener\">Remdesivir<\/a>, is out of the race now. The World Health Organization issued a conditional recommendation voicing against the use of remdesivir in hospitalized COVID-19 patients.<\/p>\n\n\n\n<p>Gilead\u2019s drug came into the news after a clinical trial demonstrated that the drug speeds up the recovery in people with severe COVID-19. This led to rampant production and purchasing deals for remdesvir worldwide. However, the advice against its use coming from the WHO has put the drugmaker in a whirlwind.&nbsp;<\/p>\n\n\n\n<p>The decision is based on a large-scale Solidarity Trial as well as 3 other randomized controlled trials led by WHO, which demonstrated no important effect on mortality, need for mechanical ventilation, time to clinical improvement, and other patient-important outcomes.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Lilly_forms_a_USD_555M_R_D_alliance_with_Precision_BioSciences_for_DMD_breakthrough_therapies\"><\/span><strong>Lilly forms a USD 555M R&amp;D alliance with Precision BioSciences for DMD breakthrough therapies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Owning a broad portfolio ranging from cancer and immuno-oncology to diabetes, psoriasis, and Crohn\u2019s disease, it\u2019s time for genome editing. Eli Lilly has announced a research collaboration and exclusive license agreement with Durham-based Precision BioSciences for leveraging Precision\u2019s ARCUS genome editing platform to research and develop potential in vivo therapies for a series of genetic disorders.&nbsp;<\/p>\n\n\n\n<p>The doublet will be exclusively focusing on <a href=\"https:\/\/www.delveinsight.com\/report-store\/duchenne-muscular-dystrophy-market\" target=\"_blank\" rel=\"noreferrer noopener\">Duchenne muscular dystrophy<\/a> (DMD), along with two other undisclosed gene targets. The deal will give a cash payment of USD 100 million to Precision along with an equity investment by Lilly of $35 million. The company will also be eligible for potential development and commercialization milestone payments per product of up to USD 420 million.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Lilly has earlier bolstered similar research collaboration and licensing agreements with Sitryx earlier in March. The collaboration with Precision BioSciences, according to the company, is another step towards the realization of Lilly\u2019s vision to develop transformational, novel therapies with the help of genome editing technology.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Innovent_receives_Chinas_NMPA_approval_for_its_Humira_Biosimilar_for_of_Polyarticular_Juvenile_Idiopathic_Arthritis\"><\/span><strong>Innovent receives China\u2019s NMPA approval for its Humira Biosimilar for of Polyarticular Juvenile Idiopathic Arthritis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Suzhou, China-based Innovent Biologics, announced the commercialization approval from China\u2019s National Medical Products Administration (NMPA) for Sulinno, an adalimumab biosimilar.<\/p>\n\n\n\n<p>The copycat of Humira (adalimumab), Sulinno is a recombinant human anti-tumor necrosis factor-alpha monoclonal antibody injection and is approved for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in China. The injection is already approved in the Chinese market for rheumatoid arthritis, ankylosing spondylitis, and psoriasis.<\/p>\n\n\n\n<p>While adherence of Humira is wide in the American and <a href=\"https:\/\/www.delveinsight.com\/whitepaper-newsletter\/biosimilars-evidence-from-europe-whitepaper\" target=\"_blank\" rel=\"noreferrer noopener\">European marke<\/a>t, its cost keeps on defying gravity. The cost of Humira deters patients and therefore, biosimilars offer high-quality and affordable alternatives.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novartis bags Mesoblast&#8217;s cell therapy, Remestemcel-L for COVID-19 ARDS The COVID-19 pandemic has put tremendous pressure on scientists to develop a safe and effective vaccine as early as possible. According to the WHO, there are currently more than 100 COVID-19 vaccine candidates under development, with several in the human trial phase. While earlier news came [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":11251,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":2,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[10830,228,268,423,639,16756],"industry":[17225],"therapeutic_areas":[17231],"class_list":["post-11242","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-covid-19","tag-eli-lilly","tag-gilead-biosciences","tag-novartis","tag-pharma-news","tag-remdesivir","industry-pharmaceutical","therapeutic_areas-infectious-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novartis&#039; COVID-19 deal; Remdesivir flunks; Humira Biosimilar<\/title>\n<meta name=\"description\" content=\"Novartis&#039; COVID-19 deal; Shattered hopes for remdesivir; Lilly&#039;s R&amp;D pact with Precision; Innovent&#039;s Humira Biosimilar\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-novartis-lilly-innovent\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis&#039; COVID-19 deal; Remdesivir flunks; Humira Biosimilar\" \/>\n<meta property=\"og:description\" content=\"Novartis&#039; COVID-19 deal; Shattered hopes for remdesivir; Lilly&#039;s R&amp;D pact with Precision; Innovent&#039;s Humira Biosimilar\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-novartis-lilly-innovent\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-24T05:45:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-02-10T06:12:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/24174843\/recent-pharma-news-and-updates-for-gilead-novartis-lilly-innovent.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"470\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novartis' COVID-19 deal; Remdesivir flunks; Humira Biosimilar","description":"Novartis' COVID-19 deal; Shattered hopes for remdesivir; Lilly's R&D pact with Precision; Innovent's Humira Biosimilar","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-novartis-lilly-innovent","og_locale":"en_US","og_type":"article","og_title":"Novartis' COVID-19 deal; Remdesivir flunks; Humira Biosimilar","og_description":"Novartis' COVID-19 deal; Shattered hopes for remdesivir; Lilly's R&D pact with Precision; Innovent's Humira Biosimilar","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-novartis-lilly-innovent","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-11-24T05:45:08+00:00","article_modified_time":"2023-02-10T06:12:02+00:00","og_image":[{"width":772,"height":470,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/24174843\/recent-pharma-news-and-updates-for-gilead-novartis-lilly-innovent.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-novartis-lilly-innovent","url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-novartis-lilly-innovent","name":"Novartis' COVID-19 deal; Remdesivir flunks; Humira Biosimilar","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-novartis-lilly-innovent#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-novartis-lilly-innovent#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/24174843\/recent-pharma-news-and-updates-for-gilead-novartis-lilly-innovent.png","datePublished":"2020-11-24T05:45:08+00:00","dateModified":"2023-02-10T06:12:02+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Novartis' COVID-19 deal; Shattered hopes for remdesivir; Lilly's R&D pact with Precision; Innovent's Humira Biosimilar","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-novartis-lilly-innovent"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-gilead-novartis-lilly-innovent#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/24174843\/recent-pharma-news-and-updates-for-gilead-novartis-lilly-innovent.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/24174843\/recent-pharma-news-and-updates-for-gilead-novartis-lilly-innovent.png","width":772,"height":470,"caption":"recent-pharma-news-and-updates-for-gilead-novartis-lilly-innovent"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/24174843\/recent-pharma-news-and-updates-for-gilead-novartis-lilly-innovent-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">COVID-19<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Eli Lilly<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gilead Biosciences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">remdesivir<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">COVID-19<\/span>","<span class=\"advgb-post-tax-term\">Eli Lilly<\/span>","<span class=\"advgb-post-tax-term\">Gilead Biosciences<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">remdesivir<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Nov 24, 2020","modified":"Updated on Feb 10, 2023"},"absolute_dates_time":{"created":"Posted on Nov 24, 2020 11:15 am","modified":"Updated on Feb 10, 2023 11:42 am"},"featured_img_caption":"recent-pharma-news-and-updates-for-gilead-novartis-lilly-innovent","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11242","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=11242"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11242\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/11251"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=11242"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=11242"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=11242"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=11242"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=11242"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}